Monday, December 22, 2025 | 12:45 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Covid vaccines may become a viable business, but that's not good news

Vaccines are not consumer products made by pharmaceutical industry: they are infrastructure.

Photo: Bloomberg
premium

Photo: Bloomberg

David Fickling | Bloomberg Opinion
For most of us, the growing evidence that the efficacy of Covid vaccines is declining over time should be a cause of worry. For the drug companies that have spent billions of dollars developing them, it’s a once-in-a-lifetime opportunity.

Recent studies on vaccine effectiveness have led to a run of orders for boosters in recent weeks. The U.S. will start distributing extra shots beginning Sept. 20th, and expects to roll out about 100 million doses in the coming months. Shortening the window before a third dose from eight to as little as five months was being discussed, President Joe Biden said